People treated for hepatitis C have unexpectedly high rate of liver cancer recurrence
Portugal's roll-out of HCV therapy with DAAs achieves impressive results
DAAs achieve excellent outcomes in real-world settings
Sofosbuvir/velpatasvir cures HCV in 95% of people with HCV and HIV co-infection
Six weeks of sofosbuvir/ledipasvir is enough to cure acute hepatitis C in HIV-negative people
Low-cost generic hepatitis C drugs match branded products in viral response
Shifting hepatitis C treatment to primary care providers could expand availability
Sofosbuvir/velpatasvir + GS-9857 works well for treatment-experienced hepatitis C patients
Hepatitis C treatment may not be enough to stop the progress of advanced liver disease, or reduce liver transplant need
